Status:
COMPLETED
A Comparison of Efficacy and Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil and Propofol-remifentanil
Lead Sponsor:
Yonsei University
Conditions:
Early Gastric Cancer Patients Who Were Scheduled for Endoscopic Submucosal Dissection
Eligibility:
All Genders
20-90 years
Phase:
NA
Brief Summary
Adequate, safe sedation is essential for Endoscopic submucosal dissection. Dexmedetomidine is a potent and selective a2-adrenoceptor agonist used for sedative and analgesic effects, but it is limited ...
Eligibility Criteria
Inclusion
- Age ≥20
- American Society of Anaesthesiologists(ASA) physical status classification I\~III
- Early gastric cancer patients who were scheduled for Endoscopic submucosal dissection
Exclusion
- Age \< 20
- American Society of Anaesthesiologists(ASA) physical status classification IV
- those with end-organ diseases (i.e. heart failure, respiratory failure, hepatic failure, renal failure)
- known drug allergies or history of drug abuse
- psychological disease
Key Trial Info
Start Date :
October 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01920113
Start Date
October 1 2012
End Date
March 1 2013
Last Update
January 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Anesthesiology & Pain Medicine, Yonsei university college of medicine
Seoul, South Korea, 120-752